Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2024-04-19 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
《独立董事工作制度》
Governance Information Classification · 100% confidence The document is titled '赛隆药业集团股份有限公司 独立董事工作制度' which translates to 'Independent Director Work System of Sailong Pharmaceutical Group Co., Ltd.' It details the governance structure, roles, responsibilities, nomination, election, and operational procedures of independent directors within the company. It references compliance with company law, securities law, and stock exchange rules, focusing on governance practices rather than financial data or report announcements. There is no indication of financial statements, audit results, earnings, or capital changes. The document is a governance framework outlining internal rules and board structure related to independent directors. Therefore, it fits the category of Governance Information (CGR). The document length (7991 characters) and content confirm it is a full governance report, not a brief announcement or certification.
2024-04-19 Chinese
《会计师事务所选聘制度》
Governance Information Classification · 95% confidence The document is a detailed policy and procedural document regarding the selection and appointment of the company's external audit firm. It outlines the rules, qualifications, procedures, supervisory responsibilities, and penalties related to the appointment and replacement of the accounting firm responsible for auditing the company's annual financial statements. It does not contain any actual financial data, audit reports, or financial statements. It is not an announcement of a report but a governance document related to audit firm selection and oversight. Therefore, it fits best under the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2024-04-19 Chinese
2023年年度审计报告
Regulatory Filings
2024-04-19 Chinese
《独立董事专门会议制度》
Governance Information Classification · 95% confidence The document is a detailed internal governance policy regarding the procedures and rules for independent directors' special meetings at 赛隆药业集团股份有限公司. It outlines meeting protocols, voting procedures, responsibilities, and confidentiality obligations. There is no financial data, no mention of financial results, no shareholder voting results, no announcements of report publications, or any other regulatory filings. The content is focused on governance practices and board procedures, which fits the definition of Governance Information (CGR). The document length is 2175 characters, which is relatively short but contains substantive governance content, not just an announcement or summary. Therefore, the appropriate classification is CGR with high confidence.
2024-04-19 Chinese
关于2023年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2023 annual profit distribution plan of the company, including details on dividends to be paid to shareholders. It includes information about the board and supervisory committee meetings approving the plan and states that the plan will be submitted to the 2023 annual shareholders meeting for approval. The document is relatively short (1553 characters) and primarily serves to inform shareholders about the dividend proposal rather than presenting full financial statements or detailed financial analysis. It does not contain comprehensive financial data or a full annual report. Therefore, it fits best as a Notice of Dividend Amount (DIV) announcement.
2024-04-19 Chinese
2023年度监事会工作报告
Audit Report / Information Classification · 95% confidence The document is titled '2023 年度监事会工作报告' which translates to '2023 Supervisory Board Work Report'. It details the supervisory board's activities, meetings, opinions on company operations, financial status, related party transactions, external guarantees, internal control self-evaluation, insider information management, and information disclosure management for the year 2023. The document is a comprehensive report on the supervisory board's work and oversight during the fiscal year 2023. It is not an announcement or a brief summary but a detailed report. This type of document aligns with the category of Audit Report / Information (AR), as it includes supervisory board oversight and audit-related content but is not a full Annual Report (10-K). The document length is 2733 characters, which is relatively short but contains substantive content typical of an audit or supervisory report rather than a mere announcement or certification. Therefore, the best classification is AR with high confidence. FY 2023
2024-04-19 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.